Tag: Gilgamesh Pharmaceuticals

Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020

Post published:September 21, 2023
Post category:Press Release

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

Post published:December 15, 2022
Post category:Press Release

Gilgamesh Announces Clinical Candidates For Two Programs With First In Human Dosing to Begin in Late 2022

Post published:March 24, 2022
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Insights
Jobs
Data
Subscribe to Pα+
Contact

Insights and interviews delivered to your inbox. No spam, just valuable information.

Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020

Gilgamesh Pharmaceuticals Raises $39 Million Series B to Advance Mental Health Treatments

Gilgamesh Announces Clinical Candidates For Two Programs With First In Human Dosing to Begin in Late 2022

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights